[Current research status and progress in comprehensive diagnosis and treatment of pancreatic cancer in the era of targeted therapy].
[Current research status and progress in comprehensive diagnosis and treatment of pancreatic cancer in the era of targeted therapy].
复制标题
DOI：
10.3760/cma.j.issn.0529-5815.2020.01.006
复制
发表时间：
2020-01-01
期刊：
影响因子：
--
通讯作者：
Yang, Y M
中科院分区：
文献类型：
--
作者：
Zhang, Z K;Yang, Y M
在世界范围内，胰腺癌的发病率持续呈上升趋势。它是临床上最具挑战性的恶性肿瘤之一，其特点是早期诊断困难，手术切除率低，预后差。由于其显著的遗传异质性，PC患者在疾病进展、临床疗效、放化疗敏感性、预后等方面存在显著的个体差异。需要深入研究不同PC亚型的分子生物学特征及其与临床表现和放化疗敏感性的关系，从而制定相应的靶向治疗策略。这不仅是PC形态分类向分子分型创新的根本依据，也是实现治疗模式由“不同病的标准治疗策略”向“同一病的不同策略治疗”转变的前提。本文综述了靶向治疗时代PC综合诊治的几个热点问题，并对其未来发展进行了展望。
The incidence of pancreatic cancer (PC) has continuously shown an upward trend all over the world. It remains one of the most challenging malignant tumors in clinical practice and is characterized by difficult diagnosis in early stages, low surgical resection rate and poor prognosis. Due to its significant genetic heterogeneity, there are notable individual differences in disease progression, clinical efficacy, sensitivity to chemoradiotherapy, and prognosis among PC patients. In-depth study is needed to reveal the molecular biological characteristics of different PC subtypes and their correlation with clinical manifestations and chemoradiotherapy sensitivity, which could contribute to develop corresponding targeted therapeutic strategies.It is not only the fundamental basis for the innovation of PC morphological classification to molecular subtyping, but also a prerequisite for achieving a shift in treatment mode from "standard therapeutic strategy for different diseases" to "treat the same disease with different strategies" .This article reviews several hot issues on the comprehensive diagnosis and treatment of PC in the era of targeted therapy and prospects its future development.